Comparative Pharmacology
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus RAUDIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus RAUDIXIN.
FENOLDOPAM MESYLATE vs RAUDIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
None Documented
None Documented
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Category C
Category C
Antihypertensive
Antihypertensive